两种治疗肝硬化低蛋白血症方案的成本—效果分析

目的 比较应用重组人生长激素（rhGH)和人血清白蛋白（HSA）治疗肝硬化低蛋白血症的疗效、不良反应及成本－效果对比。方法 运用药物经济学成本－效果分析方法,对rhGH和HSA治疗肝硬化低蛋白血症的疗效及成本进行评价。结果 rhGH和HSA治疗肝硬化低蛋白血症,治疗后第4周有效率分别为75．0％、83．3％,成本效果比分别为68．4、51．0。治疗后第8周有效率分别为87．5％、54．2％,成本效果比分别为55．0、78．5。结论 rhGH能有效治疗肝硬化低蛋白血症,能明显提高白蛋白含量并有较长的疗效,从远期看,成本效果比优于HSA。

A Comprison of Cost-effectiveness between Recombinant Human Growth Hormone and Human Serum Albumin in Treating Liver Cirrhosis with Hypoproteinemia

Objective To compare the therapeutic effects, adverse reactions and the costs between recombinant human growth hormone(rhGH) and human serum albumin(HSA) on treatment of liver cirrhosis patients with hypoproteinemia.Methods Using pharmacoeconomic cost-effectiveness analysis, rhGH was compared with HSA in treatment of 48 cases (divided into two groups) liver cirrhosis patients with hypoproteinemia.Results After 4 weeks treatment, the effective rate of rhGH and HSA was 75.0% and 83.3%,the cost-effectiveness ratios were 68.4?51.0 respectively.After 8 weeks treatment,the effective rate of rhGH and HSA was 87.5% and 54.2%,the cost-effectiveness ratios were 55.0?78.5 respectively.Conclusions rhGH can effectively treat liver cirrhosis with hypoproteinemia,it can obviously increase serum albumin level,stand the effects for a longer-term,and its cost-effectiveness ratio is superior to that of HSA.